- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07470320
Plazentabiologie in Gesundheit und Krankheit
Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.
A major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.
This single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and/or uterine vein blood samples.
Through examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The study is a non-interventional, observational study focused on sample collection and laboratory-based analyses to investigate the role of placental EVs and soluble factors in maternal and fetal health. The study will focus on understanding the molecular mechanisms underlying pre-eclampsia, gestational diabetes mellitus and fetal growth restriction, with the ultimate aim of identifying biomarkers and therapeutic targets. To achieve this, the study will recruit participants with healthy, pathological and predisposed pregnancies alongside non-pregnant healthy controls.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Professor Manu Vatish
- Telefonnummer: +441865 221009
- E-Mail: manu.vatish@wrh.ox.ac.uk
Studienorte
-
-
-
Oxford, Vereinigtes Königreich
- Rekrutierung
- Oxford University Hospitals NHS Foundation Trust
-
Kontakt:
- Clinical Research Group
- Telefonnummer: +441865 221107
- E-Mail: clinicalresearchgroup@wrh.ox.ac.uk
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions.
Participants will include:
- Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses.
- Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention.
- Pregnant women with healthy pregnancies to understand normal EV release and immune regulation.
- Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes.
Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.
Beschreibung
Inclusion Criteria:
-
Female, aged 18 years or above
-
Willing and able to give informed consent for participation in the study
-
Able to read and understand written and spoken English to comprehend study materials and give informed consent
-
Non-pregnant women in good general health OR pregnant women who fall into one of the following:
- Healthy pregnancy
- Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria
- Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy
- Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities
- Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies
Exclusion Criteria:
- Non-pregnant participants with active health conditions that could confound study outcomes
- Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: OTHER
- Zeitperspektiven: OTHER
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Schwangere Frauen mit Präeklampsie-Diagnose
|
There are no interventions for this study |
|
Schwangere Frauen mit diagnostiziertem Gestationsdiabetes mellitus
|
There are no interventions for this study |
|
Schwangere Frauen mit diagnostizierter fetaler Wachstumsrestriktion
|
There are no interventions for this study |
|
Gesunde schwangere Frauen
|
There are no interventions for this study |
|
Gesunde nicht schwangere Frauen
|
There are no interventions for this study |
|
Schwangere Frauen mit Prädisposition für Präeklampsie
|
There are no interventions for this study |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Enhanced understanding of the molecular and cellular mechanisms linking placental EVs to maternal systemic inflammation in PET and GDM.
Zeitfenster: Baseline and at delivery
|
Quantitative (number of particles/ml) and qualitative differences (protein cargo) in EV profiles |
Baseline and at delivery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Quantitative and qualitative differences in inflammatory immune cells
Zeitfenster: baseline and delivery
|
Quantitative (cells/ml) and qualitative (protein and RNA composition/mg cell) will be measured |
baseline and delivery
|
|
Sensitivity, specificity and predictive value of EVs for identifying PET, GDM and other pregnancy complications
Zeitfenster: Baseline and delivery
|
Standard statistical analysis of EV parameters against clinical endpoints to derive sensitivity, specificity and PPV/NPV in these disease conditions |
Baseline and delivery
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Erkrankungen des endokrinen Systems
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Stoffwechselerkrankungen
- Schwangerschaftskomplikationen
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Fötale Krankheiten
- Wachstumsstörungen
- Hypertonie
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Pathologische Zustände, Anzeichen und Symptome
- Ernährungs- und Stoffwechselerkrankungen
- Schwangerschaftsdiabetes
- Präeklampsie
- Fötale Wachstumsverzögerung
- Bluthochdruck, schwangerschaftsbedingt
Andere Studien-ID-Nummern
- 18939
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .